Program Goals

Overview of Following Talks

Major Outcomes in MS

Disease-Modifying Therapies

Interferon Beta:

Mechanisms of Action

Interferon Beta:

Pivotal Trials — CIS and RRMS

Trials of Interferon Beta in CIS

BENEFIT Trial: Interferon Beta-1b for CIS

REFLEX Trial: Interferon Beta-1aSC in Patients With CIS

Interferon Beta-1b in SPMS:

European and North American Trials

Mortality for Interferon Beta-1b vs Placebo

The Challenge of Choice

The Physician’s Role

DMT Choice Factors

Case 1: Dan

What Would You Tell This Patient?

What Is the Single Most Important Therapeutic Issue at This Point?

Is His History of Depression a Contraindication to Using an

Interferon-Beta?

What DMT Would You Recommend?

Reviewing Treatment Options

Interferon Beta and Depression

Interferon Beta and Depression (cont)

Interferon Beta: Positives

Interferon Beta: Concerns

Case 2: Dana

Is Interferon Beta a Good Choice for This Patient?

Interferon Beta Issues

Interferon Beta Issues (cont)

Summary

A Multitude of Factors Contributeto Optimal MS Management

Case Study 1: Lisa

Case Study 1: Lisa (cont)

Case Study 1: Lisa (cont)

Management of Adverse Therapeutic Effects

Management of Adverse Therapeutic Effects (cont)

Case Study 1: Lisa (cont)

Case Study 1: Lisa (cont)

Case Study 2: Bill

Case Study 2: Bill (cont)

What Would Your Recommendation

Be?

Case Study 2: Bill (cont)

What Are Your Next Steps?

Case Study 2: Bill (cont)

Case Study 2: Bill (cont)

How Do You Begin to Counsel Bill?

Case Study 2: Bill (cont)

What Are Your Next Steps?

Case Study 2: Bill (cont)

Case 1: MRI

Would You Consider a Change in Therapy for This Patient?

How Many Attacks Would You Allow a Patient to Have in a Given Year Before You Recommend a Change in Therapy?

How Likely Are You to Change Therapy for a Patient Who Has No Clinical Symptomatology or Exacerbations But With 1-2 New MRI Lesions?

Case 2

What Would You Do?

If You Make a Switch, What Would You Switch To?

MRI

Breakthrough Disease Facts

Why Ascertain Adherence?

Assessing Therapy — Factors to Consider

Risk Factors Contributing to "More Aggressive" Disease

Suboptimal Response: Clinical Criteria

Suboptimal Response: MRI Criteria

Therapeutic Response

Suboptimal Response: Proposed Criteria

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)